

# VIBRANT AMERICA DEMO

Name: VIBRANT AMERICA DEMO  
Date of Birth: 01-01-1111  
Gender: Male  
Age: 01  
Height:  
Weight:  
Fasting: FASTING

Telephone: 000-000-0000  
Street Address:  
Email:

FINAL REPORT

Accession ID: 2311080858

## Provider Information

Practice Name: DEMO CLIENT, MD  
Provider Name: DEMO CLIENT, MD  
Phlebotomist: 0

Telephone: 000-000-0000  
Address: 3521 Leonard Ct, Santa Clara, CA 95054

## Report Information

Current Result Previous Result In Control Moderate Risk

## Specimen Information

| Sample Type | Collection Time        | Received Time          | Report               | Final Report Date      |
|-------------|------------------------|------------------------|----------------------|------------------------|
| Serum       | 2023-12-19 11:00 (PDT) | 2023-12-20 12:05 (PDT) |                      |                        |
| EDTA        | 2023-12-19 11:00 (PDT) | 2023-12-20 12:05 (PDT) | Vibrant America - P2 | 2023-12-28 08:54 (PDT) |
| Plasma      | 2023-12-19 11:00 (PDT) | 2023-12-20 12:05 (PDT) |                      |                        |

Regulation Statement: Tests indicated with an asterisk (\*) were developed by and performance characteristics were determined by Vibrant America. These tests are not FDA-cleared or approved. The performance characteristics were determined and validated by Vibrant America in a manner consistent with CLIA requirements. The laboratory is regulated under CLIA and is CAP certified hence qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. Tests indicated with <sup>1</sup> were performed at Vibrant Genomics. Laboratory Director: Dr. Claude O. Burdick, M.D. CLIA: 05D2078809. CLF: 00346278. Vibrant America Clinical Laboratory, 3521 Leonard Ct, Santa Clara, CA 94054. Phone: +1(866)364-0963; Fax: +1(650)508-8260; Email: support@vibrant-america.com.



TNP Test not performed

R&L Refer to risks and limitations at the end of report

Notes Refer to Lab notes at the end of the table




## Rheumatoid Arthritis

| Test Name     | Current | Previous            | Result | Reference |
|---------------|---------|---------------------|--------|-----------|
| hs-CRP (mg/L) | 0.5     | 0.6<br>(06-15-2023) |        | ≤0.9      |



## Cardiac Health Panel

| Apolipoproteins            | Current | Previous              | Result | Reference |
|----------------------------|---------|-----------------------|--------|-----------|
| Apo A-1 (mg/dL)            | 239     | 144<br>(06-15-2023)   |        | ≥140.0    |
| Apo B (mg/dL)              | 40      | 55<br>(06-15-2023)    |        | ≤89.0     |
| Apo B: Apo A-1             | 0.17    | 0.38<br>(06-15-2023)  |        | ≤0.59     |
| Inflammation               | Current | Previous              | Result | Reference |
| Homocysteine (μmol/L)      | 8       | 10<br>(06-15-2023)    |        | ≤9.0      |
| MPO* (pmol/L)              | 736.0   | 539.0<br>(06-15-2023) |        | ≤599.9    |
| ox-LDL* (U/L)              | 24.1    | 29.2<br>(06-21-2023)  |        | ≤60.0     |
| PLAC (nmol/min/mL)         | 105     | 100<br>(06-15-2023)   |        | ≤224.0    |
| LDL Direct                 | Current | Previous              | Result | Reference |
| LDL Direct (mg/dL)         | 90      | 55<br>(06-15-2023)    |        | ≤99.0     |
| Lipids                     | Current | Previous              | Result | Reference |
| Cholesterol, Total (mg/dL) | 254     | 120<br>(06-15-2023)   |        | ≤199.0    |
| HDL Direct (mg/dL)         | 153     | 49<br>(06-15-2023)    |        | ≥66.0     |
| LDL Calculation (mg/dL)    | 88      | 56<br>(06-15-2023)    |        | ≤99.0     |
| Triglyceride (mg/dL)       | 67      | 76<br>(06-15-2023)    |        | ≤149.0    |
| LipoProtein Markers        | Current | Previous              | Result | Reference |
| Lp(a) (mg/dL)              | <7      | <7<br>(06-15-2023)    |        | ≤29.0     |
| sdLDL* (mg/dL)             | 8.4     | 11.2<br>(06-15-2023)  |        | ≤50.0     |

## Glycemic Control

| Test Name                       | Current | Previous            | Result   | Reference  |
|---------------------------------|---------|---------------------|--|------------|
| Hemoglobin A1c (%)              | 6.0     | 5.8<br>(06-15-2023) |  | ≤5.6       |
| Glucose(Diabetes) (mg/dL)       | 88      | 73<br>(06-15-2023)  |  | 70.0-100.0 |
| Glycated Serum Protein (umol/L) | 234     | 188<br>(06-15-2023) |  | ≤285.0     |


## Insulin Resistance

| Test Name            | Current | Previous             | Result   | Reference  |
|----------------------|---------|----------------------|--|------------|
| Adiponectin* (ug/mL) | 34.6    | 21.3<br>(06-15-2023) |  | 13.0-150.0 |
| Ferritin (ng/mL)     | 24      | 47<br>(06-15-2023)   |  | 13.0-150.0 |









### Adiponectin:

| Body Mass Index (BMI)  | Male       | Female     |
|--|------------|------------|
| kg/meters-squared  | ug/mL      | ug/mL      |
| <25  | 4.7 - 49.2 | 8.5 - 56.2 |
| 25-30  | 3.8 - 35.0 | 6.1 - 47.2 |
| >30  | 2.2 - 32.6 | 4.9 - 42.1 |
| Body Mass Index (BMI) = (weight in Kg) / (height in metres) <sup>2</sup> |            |            |

## Beta Cell Function

| Test Name       | Current | Previous            | Result   | Reference |
|-----------------|---------|---------------------|--|-----------|
| Insulin (µU/mL) | 8.5     | 1.6<br>(06-15-2023) |  | 2.6-24.9  |

## Hormones

| Test Name                    | Current | Previous              | Result   | Reference  |
|------------------------------|---------|-----------------------|--|------------|
| Cortisol (µg/dL)             | 7.5     | 6.3<br>(06-15-2023)   |    | 6.2-19.4   |
| DHEA-S (µg/dL)               | 38.9    | 27.2<br>(06-15-2023)  |    | 18.9-205.0 |
| Dihydrotestosterone* (ng/dl) | 25.8    | <3.2<br>(06-23-2023)  |    | 6.5-50.1   |
| Estradiol (pg/mL)            | 80.1    | 107.0<br>(06-15-2023) |  |            |
| FSH (mIU/mL)                 | 22.9    | 25.0<br>(06-15-2023)  |  |            |
| LH (mIU/mL)                  | 30.0    | 27.9<br>(06-15-2023)  |  |            |
| Pregnenolone* (ng/mL)        | 0.84    | 1.37<br>(06-21-2023)  |    | 0.31-3.8   |
| Prolactin (ng/mL)            | 15.50   | 25.70<br>(06-15-2023) |    | 4.79-23.3  |
| Progesterone (ng/mL)         | 3.220   | 2.510<br>(06-15-2023) |  |            |
| Parathyroid Hormone (pg/mL)  | 37      | 54<br>(06-15-2023)    |   | 15.0-65.0  |
| SHBG (nmol/L)                | 170.0   | 180.0<br>(06-15-2023) |  | 17.3-125.0 |
| Testosterone, Total (ng/dL)  | 48.4    | 2.5<br>(06-15-2023)   |  | 4.6-312.6  |

### Estradiol




### FSH

### LH

### Progesterone

| Phase                   | Reference Range      | Phase         | Reference Range   | Phase         | Reference Range   | Phase         | Reference Range     |
|-------------------------|----------------------|---------------|-------------------|---------------|-------------------|---------------|---------------------|
| FOLLICULAR              | 12.4 - 233 pg/mL     | FOLLICULAR    | 3.5 - 12.5 mIU/mL | FOLLICULAR    | 2.4 - 12.6 mIU/ml | FOLLICULAR    | 0.057 - 0.893 ng/mL |
| OVULATION               | 41.0 - 398 pg/mL     | OVULATION     | 4.7 - 21.5 mIU/mL | OVULATION     | 14 - 95.6 mIU/mL  | OVULATION     | 0.121 - 12.0 ng/mL  |
| LUTEAL                  | 22.3 - 341 pg/mL     | LUTEAL        | 1.7 - 7.7 mIU/mL  | LUTEAL        | 1 - 11.4 mIU/mL   | LUTEAL        | 1.83 - 23.9 ng/mL   |
| Postmenopause           | <5 - 138 pg/mL       | Postmenopause | 25.8-134.8 mIU/mL | Postmenopause | 7.7-58.5 mIU/mL   | Postmenopause | 0 - 0.126 ng/mL     |
| PREGNANCY 1st trimester | 154 - 3243 pg/ml     |               |                   |               |                   |               |                     |
| PREGNANCY 2nd trimester | 1561 - 21280 pg/ml   |               |                   |               |                   |               |                     |
| PREGNANCY 3rd trimester | 8525 - > 30000 pg/ml |               |                   |               |                   |               |                     |

## Other Markers

| Test Name           | Current | Previous             | Result   | Reference  |
|---------------------|---------|----------------------|--|------------|
| Cystatin C (mg/L)   | 0.87    | 0.74<br>(06-15-2023) |  | 0.61-0.95  |
| Human IGF-I (ng/mL) | 93      | 41<br>(06-16-2023)   |  | 43.0-220.0 |
| Leptin (ng/mL)      | 11.6    | 11.7<br>(06-21-2023) |  |            |
| Uric Acid (mg/dL)   | 3.5     | 3.5<br>(06-15-2023)  |  | 2.4-5.7    |

### Leptin:

| Age (Years) | Body Mass Index (BMI) (kg/meters-squared) | Male (ng/mL) | Female (ng/mL) |
|-------------|---|--------------|----------------|
| 5-9         | All Ranges                                | 1.1-16.8     | 1.1-16.8       |
| 10-13       | All Ranges                                | 1.4-16.5     | 1.4-16.5       |
| 14-17       | All Ranges                                | 1.1-24.9     | 1.1-24.9       |
| >17         | 18-25                                     | 1.1-13.4     | 4.7-23.7       |
| >17         | 25-30                                     | 1.8-19.9     | 8.0-38.9       |

Body Mass Index (BMI) = (weight in Kg) / (height in metres)<sup>2</sup>

## Risk and Limitations

All tests has been verified and its performance characteristics validated by Vibrant America LLC., a CLIA and CAP certified lab. Clinical history and current symptoms of the individual must be considered by the healthcare provider prior to any interventions. Test results should be used as one component of a healthcare provider's clinical assessment.

Vibrant America has effective procedures in place to protect against technical and operational problems. However, such problems may still occur. Examples include failure to obtain the result for a specific test due to circumstances beyond Vibrant's control. Vibrant may re-test a sample to obtain these results but upon re-testing the results may still not be obtained. As with all medical laboratory testing, there is a small chance that the laboratory could report incorrect results. A tested individual may wish to pursue further testing to verify any results.

Vibrant America makes no claims as to the diagnostic or therapeutic use of its tests or other informational materials. Vibrant America reports and other information do not constitute medical advice and are not a substitute for professional medical advice. Please consult your healthcare practitioner for questions regarding test results, or before beginning any course of medication, supplementation, or dietary changes.

SAMPLE